SLP
Get informed when a big investor buys or sells
+ FollowUndervalued by 32.4% based on the discounted cash flow analysis.
| Market cap | $368.70 Million |
|---|---|
| Enterprise Value | $339.40 Million |
| Dividend Yield | $0.24 (-) |
| Earnings per Share | $-3.22 |
| Beta | 1.31 |
| Outstanding Shares | 20,170,000 |
| P/E Ratio | 44.49 |
|---|---|
| PEG | -42.24 |
| Price to Sales | 4.56 |
| Price to Book Ratio | 3.04 |
| Enterprise Value to Revenue | 4.14 |
| Enterprise Value to EBIT | -5.25 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 6.60% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 1.66%▼ 78.43% |
|---|---|
| Total Invested | $6.12M▼ 96.80% |
| Investors Holding | 16▼ 144.00% |
No data
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and...